探索抑郁症和抗抑郁药对COVID-19的因果关系
Li Fu1, Ancha Baranova2, Hongbao Cao3
1Department of Psychiatry, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.
Journal of affective disorders
|May 27, 2024
概括
对抑郁症的遗传倾向增加了COVID-19严重结果的风险,包括严重疾病和住院治疗. 然而,抗抑郁药的使用没有与COVID-19风险或严重程度产生因果关系.
科学领域:
- 精神病学和传染性疾病
- 遗传流行病学遗传流行病学
- 药物基因组学 药物基因组学
背景情况:
- 现有研究表明,抑郁症与COVID-19风险增加之间存在联系.
- 大型抑郁症 (MDD) 和COVID-19严重程度之间的因果关系需要验证.
- 抗抑郁药对COVID-19风险的影响目前尚不清楚.
研究的目的:
- 使用孟德尔随机化研究抑郁症对COVID-19结果的潜在因果影响.
- 评估抗抑郁药使用对COVID-19风险和严重性的因果影响.
主要方法:
- 孟德尔随机化 (MR) 分析利用全基因组关联研究 (GWAS) 总结数据.
- 对抑郁症 (N=1,349,887),抗抑郁药使用 (N=106,785) 和COVID-19结果 (SARS-CoV-2感染,N=2,597,856;住院COVID-19,N=2,095,324;危急COVID-19,N=1,086,211) 的大规模数据集的分析.
- 应用逆方差加权 (IVW) 方法来评估因果关系.
主要成果:
- 在对抑郁症的遗传责任与严重COVID-19 (OR:1.28) 的风险增加,住院COVID-19 (OR:1.23) 和SARS-CoV-2感染 (OR:1.06) 之间发现了显著的因果关系.
- 抗抑郁药的使用并没有与任何COVID-19结果产生因果关系,包括严重疾病 (OR:1.05),住院 (OR:1.01) 或SARS-CoV-2感染 (OR:1.03).
结论:
- 对抑郁症的遗传倾向与增加对COVID-19及其严重表现的易感性有关.
- 抗抑郁药物药物似乎没有因果影响COVID-19风险或严重程度.
- 研究结果表明,抗抑郁药可能会减轻抑郁症对COVID-19结果的不良影响.
相关概念视频
Depressive Disorders: Etiology
68
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
68
Depression: Overview
238
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
238
Stress and Mental Health
110
Chronic stress profoundly affects mental health, significantly influencing mood, behavior, and overall quality of life. Research closely links chronic stress with mental health conditions such as depression, anxiety, and substance use disorders. Ongoing exposure to stress can lead to physiological and psychological changes, initiating a cycle of emotional distress and maladaptive coping mechanisms.
Individuals with depression often experience challenges in both their personal and professional...
Individuals with depression often experience challenges in both their personal and professional...
110
Antidepressant Drugs: MAOIs and Other Agents
225
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
225
Antidepressant Drugs: Overview
450
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
450
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
370
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
370


